227 related articles for article (PubMed ID: 22154278)
1. Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC).
Reungwetwattana T; Weroha SJ; Molina JR
Clin Lung Cancer; 2012 Jul; 13(4):252-66. PubMed ID: 22154278
[TBL] [Abstract][Full Text] [Related]
2. The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models.
Normant E; Paez G; West KA; Lim AR; Slocum KL; Tunkey C; McDougall J; Wylie AA; Robison K; Caliri K; Palombella VJ; Fritz CC
Oncogene; 2011 Jun; 30(22):2581-6. PubMed ID: 21258415
[TBL] [Abstract][Full Text] [Related]
3. ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development.
Scagliotti G; Stahel RA; Rosell R; Thatcher N; Soria JC
Eur J Cancer; 2012 May; 48(7):961-73. PubMed ID: 22397764
[TBL] [Abstract][Full Text] [Related]
4. Targeted therapies for non-small cell lung cancer.
Dempke WC; Suto T; Reck M
Lung Cancer; 2010 Mar; 67(3):257-74. PubMed ID: 19914732
[TBL] [Abstract][Full Text] [Related]
5. First-line therapy of mutated non-small cell lung cancer: an update.
Stöhlmacher-Williams J
Onkologie; 2012; 35(5):293-9. PubMed ID: 22868512
[TBL] [Abstract][Full Text] [Related]
6. New targeted therapies for non-small-cell lung cancer: a focus on the epidermal growth factor receptor.
Crawford J
J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S78-86. PubMed ID: 19795580
[TBL] [Abstract][Full Text] [Related]
7. The emerging role of biomarkers in advanced non-small-cell lung cancer.
Socinski MA
Clin Lung Cancer; 2010 May; 11(3):149-59. PubMed ID: 20439190
[TBL] [Abstract][Full Text] [Related]
8. Targeted agents in non-small cell lung cancer (NSCLC): clinical developments and rationale for the combination with thoracic radiotherapy.
Koh PK; Faivre-Finn C; Blackhall FH; De Ruysscher D
Cancer Treat Rev; 2012 Oct; 38(6):626-40. PubMed ID: 22196919
[TBL] [Abstract][Full Text] [Related]
9. Primary and secondary therapeutic strategies for EGF receptor pathway inhibition in non-small-cell lung cancer.
Batus M; Fidler MJ; Bonomi PD
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1589-99. PubMed ID: 20942630
[TBL] [Abstract][Full Text] [Related]
10. Targeted therapy for NSCLC with driver mutations.
Minuti G; D'Incecco A; Cappuzzo F
Expert Opin Biol Ther; 2013 Oct; 13(10):1401-12. PubMed ID: 23930754
[TBL] [Abstract][Full Text] [Related]
11. New targets in advanced NSCLC: EML4-ALK.
Crystal AS; Shaw AT
Clin Adv Hematol Oncol; 2011 Mar; 9(3):207-14. PubMed ID: 21475126
[TBL] [Abstract][Full Text] [Related]
12. The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC.
Gately K; O'Flaherty J; Cappuzzo F; Pirker R; Kerr K; O'Byrne K
J Clin Pathol; 2012 Jan; 65(1):1-7. PubMed ID: 22039281
[TBL] [Abstract][Full Text] [Related]
13. Beyond EGFR and ALK inhibition: unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer.
Califano R; Abidin A; Tariq NU; Economopoulou P; Metro G; Mountzios G
Cancer Treat Rev; 2015 May; 41(5):401-11. PubMed ID: 25842168
[TBL] [Abstract][Full Text] [Related]
14. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.
John T; Liu G; Tsao MS
Oncogene; 2009 Aug; 28 Suppl 1():S14-23. PubMed ID: 19680292
[TBL] [Abstract][Full Text] [Related]
15. Personalized targeted therapy in advanced non-small cell lung cancer.
Ma PC
Cleve Clin J Med; 2012 May; 79 Electronic Suppl 1():eS56-60. PubMed ID: 22614968
[TBL] [Abstract][Full Text] [Related]
16. Metastatic non-small cell lung cancer management: novel targets and recent clinical advances.
Riess JW; Wakelee HA
Clin Adv Hematol Oncol; 2012 Apr; 10(4):226-34. PubMed ID: 22706483
[TBL] [Abstract][Full Text] [Related]
17. Molecular profiling to optimize treatment in non-small cell lung cancer: a review of potential molecular targets for radiation therapy by the translational research program of the radiation therapy oncology group.
Ausborn NL; Le QT; Bradley JD; Choy H; Dicker AP; Saha D; Simko J; Story MD; Torossian A; Lu B
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e453-64. PubMed ID: 22520478
[TBL] [Abstract][Full Text] [Related]
18. Targeted therapies for non-small-cell lung cancer: biology, rationale, and preclinical results from a radiation oncology perspective.
Raben D; Helfrich B; Bunn PA
Int J Radiat Oncol Biol Phys; 2004; 59(2 Suppl):27-38. PubMed ID: 15142632
[TBL] [Abstract][Full Text] [Related]
19. Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers.
Lin E; Li L; Guan Y; Soriano R; Rivers CS; Mohan S; Pandita A; Tang J; Modrusan Z
Mol Cancer Res; 2009 Sep; 7(9):1466-76. PubMed ID: 19737969
[TBL] [Abstract][Full Text] [Related]
20. The emerging pathogenic and therapeutic importance of the anaplastic lymphoma kinase gene.
Kelleher FC; McDermott R
Eur J Cancer; 2010 Sep; 46(13):2357-68. PubMed ID: 20451371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
